Allergan's US dermatology portfolio -- which includes acne treatments Aczone, or dapsone, Azelex, or azelaic acid, and Tazorac, or tazarotene, plus dermatosis drug Cordran tape, or fludroxycortide, and acne vulgaris drug Seysara, or sarecycline -- was purchased by Spain's Almirall. The deal gives Allergan a $550 million upfront payment and up to $100 million based on portfolio earnings.
Allergan's US dermatology portfolio sold to Almirall
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.